Medtronic (MDT) Beats Stock Market Upswing: What Investors Need to Know

Medtronic (MDT) ended the recent trading session at $97.70, demonstrating a +2.33% change from the preceding day's closing price. This move outpaced the S&P 500's daily gain of 0.01%. Meanwhile, the Dow gained 0.51%, and the Nasdaq, a tech-heavy index, lost 0.28%. Coming into today, shares of the medical device company had gained 2.83% in the past month. In that same time, the Medical sector gained 4.67%, while the S&P 500 gained 4.83%. Investors will be eagerly watching for the performance of Medtronic in its upcoming earnings disclosure. The company's earnings report is set to be unveiled on November 18, 2025. The company is forecasted to report an EPS of $1.31, showcasing a 3.97% upward movement from the corresponding quarter of the prior year. Meanwhile, our latest consensus estimate is calling for revenue of $8.84 billion, up 5.26% from the prior-year quarter. Regarding the entire year, the Zacks Consensus Estimates forecast earnings of $5.62 per share and revenue of $35.83 billion, indicating changes of +2.37% and +6.82%, respectively, compared to the previous year. Additionally, investors should keep an eye on any recent revisions to analyst forecasts for Medtronic. These latest adjustments often mirror the shifting dynamics of short-term business patterns. As a result, we can interpret positive estimate revisions as a good sign for the business outlook. Our research suggests that these changes in estimates have a direct relationship with upcoming stock price performance. We developed the Zacks Rank to capitalize on this phenomenon. Our system takes these estimate changes into account and delivers a clear, actionable rating model. The Zacks Rank system, running from #1 (Strong Buy) to #5 (Strong Sell), holds an admirable track record of superior performance, independently audited, with #1 stocks contributing an average annual return of +25% since 1988. Over the past month, there's been no change in the Zacks Consensus EPS estimate. Medtronic is currently a Zacks Rank #3 (Hold). Looking at its valuation, Medtronic is holding a Forward P/E ratio of 17. For comparison, its industry has an average Forward P/E of 18.31, which means Medtronic is trading at a discount to the group. One should further note that MDT currently holds a PEG ratio of 2.51. The PEG ratio is akin to the commonly utilized P/E ratio, but this measure also incorporates the company's anticipated earnings growth rate. The Medical - Products was holding an average PEG ratio of 2.27 at yesterday's closing price. The Medical - Products industry is part of the Medical sector. With its current Zacks Industry Rank of 77, this industry ranks in the top 32% of all industries, numbering over 250. The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1. Be sure to use Zacks.com to monitor all these stock-influencing metrics, and more, throughout the forthcoming trading sessions. Research Chief Names "Single Best Pick to Double"From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.This company targets millennial and Gen Z audiences, generating nearly $1 billion in revenue last quarter alone. A recent pullback makes now an ideal time to jump aboard. Of course, all our elite picks aren’t winners but this one could far surpass earlier Zacks’ Stocks Set to Double like Nano-X Imaging which shot up +129.6% in little more than 9 months.Free: See Our Top Stock And 4 Runners UpWant the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Medtronic PLC (MDT): Free Stock Analysis ReportThis article originally published on Zacks Investment Research (zacks.com).Zacks Investment ResearchWeiter zum vollständigen Artikel bei Zacks Weiter zum vollständigen Artikel bei Zacks